<DOC>
	<DOC>NCT00661362</DOC>
	<brief_summary>Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients who have inadequate glycaemic control when treated with metformin in addition to diet and exercise.</brief_summary>
	<brief_title>Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diagnosed with Type 2 diabetes Treatment with metformin at a stable dose &gt;1500 mg/day HbA1c ≥ 7.0% and ≤10.0% Insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes) Type 1 diabetes, history of ketoacidosis, or hyperosmolar nonketonic koma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>DPP-4 inhibitors</keyword>
	<keyword>HbA1c</keyword>
	<keyword>Incretins</keyword>
</DOC>